177 related articles for article (PubMed ID: 23199019)
1. Aflibercept in lung cancer.
Neal JW; Wakelee HA
Expert Opin Biol Ther; 2013 Jan; 13(1):115-20. PubMed ID: 23199019
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
3. A preclinical and clinical review of aflibercept for the management of cancer.
Gaya A; Tse V
Cancer Treat Rev; 2012 Aug; 38(5):484-93. PubMed ID: 22264850
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
Thai HT; Veyrat-Follet C; Mentré F; Comets E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):167-80. PubMed ID: 23673444
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.
Tang PA; Cohen SJ; Kollmannsberger C; Bjarnason G; Virik K; MacKenzie MJ; Lourenco L; Wang L; Chen A; Moore MJ
Clin Cancer Res; 2012 Nov; 18(21):6023-31. PubMed ID: 22977191
[TBL] [Abstract][Full Text] [Related]
6. Emerging VEGF-receptor inhibitors for colorectal cancer.
Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor trap in non small cell lung cancer.
Riely GJ; Miller VA
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4623-7. PubMed ID: 17671153
[TBL] [Abstract][Full Text] [Related]
8. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
9. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
[TBL] [Abstract][Full Text] [Related]
10. Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer.
Perkins SL; Cole SW
Ann Pharmacother; 2014 Jan; 48(1):93-8. PubMed ID: 24259608
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
12. [New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept].
Kato S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):6-9. PubMed ID: 23306912
[TBL] [Abstract][Full Text] [Related]
13. Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.
Stewart MW
Expert Rev Clin Pharmacol; 2013 Mar; 6(2):103-13. PubMed ID: 23473589
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Subramanian J; Morgensztern D; Govindan R
Clin Lung Cancer; 2010 Sep; 11(5):311-9. PubMed ID: 20837456
[TBL] [Abstract][Full Text] [Related]
15. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management.
Cartwright TH
Clin Colorectal Cancer; 2013 Jun; 12(2):86-94. PubMed ID: 23562587
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.
Sanz-Garcia E; SaurĂ T; Tabernero J; Macarulla T
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):995-1004. PubMed ID: 25988772
[TBL] [Abstract][Full Text] [Related]
17. Ziv-aflibercept: binding to more than VEGF-A--does more matter?
Clarke JM; Hurwitz HI
Nat Rev Clin Oncol; 2013 Jan; 10(1):10-1. PubMed ID: 23149898
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
19. New antiangiogenetic agents and non-small cell lung cancer.
Gridelli C; Rossi A; Maione P
Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
[TBL] [Abstract][Full Text] [Related]
20. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
Saif MW
Anticancer Res; 2013 Jun; 33(6):2377-80. PubMed ID: 23749885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]